Breast Cancer in the Philippines: A Financing Cost Assessment Study

Authors

  • Madeleine de Rosas Valera, MD, MSc International Health Asia Pacific Management and Research Group, Inc. (APMARGIN), Bulacan, Philippines
  • Julienne Clarize P. Lechuga Asia Pacific Management and Research Group, Inc. (APMARGIN), Bulacan, Philippines
  • Lourdes Risa S. Yapchiongco, MMedSc Asia Pacific Management and Research Group, Inc. (APMARGIN), Bulacan, Philippines
  • Necy S. Juat, MD National Kidney and Transplant Institute, Quezon City, Philippines
  • Mary Juliet De Rosas Labitigan, MS Soc Dev Asia Pacific Management and Research Group, Inc. (APMARGIN), Bulacan, Philippines; Colegio De La Ciudad De Tayabas, Quezon Province, Philippines
  • Maria Lourdes E. Amarillo, MPH (Biostatistics) Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines
  • Leo M. Flores Asia Pacific Management and Research Group, Inc. (APMARGIN), Bulacan, Philippines
  • Maebel Audrey R. Joaquin, RPm, MD Asia Pacific Management and Research Group, Inc. (APMARGIN), Bulacan, Philippines
  • Adelberto R. Lambinicio Asia Pacific Management and Research Group, Inc. (APMARGIN), Bulacan, Philippines

DOI:

https://doi.org/10.47895/amp.vi0.10438

Keywords:

breast cancer, chemotherapy, mastectomy, radiation therapy, financial cost

Abstract

Objectives. The aim of the study is to estimate the cost of breast cancer diagnosis, treatment, and management in the Philippines. Specifically, it aims to identify the resource requirements and interventions related to breast cancer diagnosis, treatment, and management, measure resource volumes (number of units), learn to value resource items (unit costs), and determine the total cost of treatment per disease stage.

Methods. The study covered nine tertiary hospitals, seven of which were government hospitals and two were private hospitals, with all tertiary hospitals providing breast cancer services and accredited by Philippine Health Insurance Corporation (PHIC or PhilHealth) for the Z-Benefit Package. Interventions and services related to breast cancer included radiographic procedures, laboratory and imaging tests, chemotherapy drugs and medications, medical and surgical supplies, surgical rates (for breast surgery), accommodation, staff time and salary/professional fees, and other procedure fees. The study conducted in 2022, examined cost prices of breast cancer interventions and services from stage 1–3B.

Purposive and convenience sampling were used based on PhilHealth accreditation and willingness of hospitals to participate in the study. The study conducted a focus group discussion with oncologists, radiologists, anesthesiologists, and other health care providers to validate the clinical guideline used and to solicit inputs to the costing design, analysis framework, and tools for data collection. Data collection of financial cost information (charge price) was conducted using a set of costing matrices filled out by the various departments of the hospitals. Costs and median rates were calculated across hospitals on diagnostics and imaging tests, surgery costs of both public and private facilities, medical treatment, and radiotherapy.

Results. Breast MRI, Breast Panel, and Chest CT Scan are the top 3 most expensive diagnostic procedures ranging from PhP 8,102.00 to PhP 9,800.00 per procedure. Surgical procedures for breast cancer at private hospitals and public hospitals showed huge differences in costs. The cost of a cycle of chemotherapy ranges from PhP 596.70 to PhP 3,700.00 per session, while the cost of targeted therapy can cost up to PhP 46,394.21 per session. A year of hormone therapy ranges from PhP 3,276.00 with the use of Tamoxifen, and up to PhP 68,284.00 with Goserelin. Aromatase inhibitors such as Anastrozole and Letrozole cost from PhP 18,000 to PhP 36,000, respectively. Multiple cycles depending on the diagnosis are prescribed per patient and used in combination with other chemotherapy medications or other therapies such as targeted therapy and hormone therapy are usually taken daily up to 5 to 10 years. Conventional radiotherapy can cost up to PhP 88,150.00 covering 28 sessions, CT simulation, and CT planning.

Conclusion. This cost study provides relevant information and better perspective on benefit development for the PHIC, policy development for Department of Health on where and how to focus their support for the patient’s financial preparedness to address medical and f inancial catastrophes.

PhilHealth needs to guide the health care providers of their costing method and to develop their own integrated, interoperable, and comprehensive cost data library.

It recommends that the government allocate budget and cover for screening and assessment for earlier stage diagnosis of patients and lower health expenditure costs on cancer treatment.

 

Downloads

Published

2025-01-16

Issue

Section

Articles

How to Cite

1.
Breast Cancer in the Philippines: A Financing Cost Assessment Study. Acta Med Philipp [Internet]. 2025 Jan. 16 [cited 2025 Apr. 4];. Available from: https://actamedicaphilippina.upm.edu.ph/index.php/acta/article/view/10438